ARTICLE / CLIENT ALERT
US Federal Agencies Commit to Regulatory Enforcement of AI Systems
May 31, 2023
Read time: 9 min
In a recent joint statement, several federal agencies warned that they will commit to enforcing their separate regulations against developers, deployers and users of AI systems, specifically citing civil rights, fair competition, consumer protection and equal opportunity concerns. Federal Trade Commission (FTC) Chair Lina Khan and officials from the US Department of Justice (DOJ), the Consumer Financial Protection Bureau (CFPB) and the US Equal Employment Opportunity Commission (EEOC) each reinforced their concerns about automated systems. Their serious language, joint public commitment and previous enforcement actions in this area make this statement no simple theater.
Recent attention and increasingly widespread use of AI have led the FTC to issue a series of warnings this year about AI advertising. These warnings follow the FTC’s guidance from April 2021 on fairness and equity and its June 2022 report to study “how artificial intelligence (AI) may be used to identify, remove, or take any other appropriate action necessary to address a wide variety of specified online harms.” The FTC’s new Office of Technology, designed to “strengthen the FTC’s ability to keep pace with the technological challenges in the digital marketplace by supporting the agency’s law enforcement and policy work,” is expected to take the lead in this area.
The other federal agencies involved have each issued separate guidance in their respective fields. The use of automated decision-making has been a topic of legislative action from a variety of state and municipal actors, including California and New York City. The DOJ and EEOC have repeatedly warned about disability and employment discrimination using AI tools.
More recently, the EEOC has published a new guidance document in support of its Artificial Intelligence and Algorithmic Fairness Initiative (launched in 2021). The document released on May 18, 2023, is titled “Assessing Adverse Impact in Software, Algorithms, and Artificial Intelligence Used in Employment Selection Procedures Under Title VII of the Civil Rights Act of 1964” and is intended to aid employers and developers as they design and adopt new AI-enabled technologies.
Companies considering the use of automated decision-making tools in their hiring or employment practices are advised to pay careful attention to these regulations and legislation, which may affect existing hiring practices previously considered industry-standard.
In a press release accompanying the statement, FTC Chair Khan said:
“We already see how AI tools can turbocharge fraud and automate discrimination, and we won’t hesitate to use the full scope of our legal authorities to protect Americans from these threats[.] Technological advances can deliver critical innovation—but claims of innovation must not be cover for lawbreaking. There is no AI exemption to the laws on the books, and the FTC will vigorously enforce the law to combat unfair or deceptive practices or unfair methods of competition.”
Notably, the joint statement includes explicit warnings about deploying AI in a variety of contexts, noting:
“AI tools can be inaccurate, biased, and discriminatory by design and incentivize relying on increasingly invasive forms of commercial surveillance. The FTC has [ ] warned market participants that it may violate the FTC Act to use automated tools that have discriminatory impacts, to make claims about AI that are not substantiated, or to deploy AI before taking steps to assess and mitigate risks. Finally, the FTC has required firms to destroy algorithms or other work product that were trained on data that should not have been collected.”
In a related comment, CFPB Director Rohit Chopra argued that “Unchecked ‘AI’ poses threats to fairness and to our civil rights in ways that are already being felt.”
This federal warning is a shot across the bow for a variety of industries who may have been considering using AI in a broad set of circumstances, increasing uncertainty related to compliance in an area already fraught by concerns regarding copyright, professional ethics and simple questions to do with the effectiveness of products which may be plagued with falsehoods.
However, the tone of the publication is not simply barring these technologies, rather framing the regulatory attention as geared toward ensuring that responsible innovation occurs. As researchers focus on how to construct such responsible-AI-by-design products, companies are advised to carefully navigate this space while regulators seem to be seeking examples to be made.
Here are a few related previous publications by the agencies in question:
- The CFPB published a circular in May 2022 “confirming that federal consumer financial laws and adverse action requirements apply regardless of the technology being used.”
- The DOJ filed a statement of interest in federal court in January 2023 applying the Fair Housing Act to “algorithm-based tenant screening services.”
- The EEOC issued a technical assistance document in May 2022 “explaining how the Americans with Disabilities Act applies to the use of software, algorithms, and AI to make employment-related decisions about job applicants and employees.”
As mentioned above, the FTC has historically and recently been very active in this space, publishing:
- Emphasis on the importance of consumer trust in AI technology and concerns about how companies deploy AI technology, including generative AI tools;
- Warnings on AI involvement in unfair business practices;
- Significant concerns related to inaccuracy, bias and discrimination; and
- Warnings on two occasions this year about potential violation of the FTC Act from use of automated tools with discriminatory impact or overselling AI products.
On two occasions in the past two years, the FTC has enforced such attention, requiring firms to “destroy algorithms or other work product that were trained on data that should not be collected.”
When the agencies are marching in tandem, industry members and AI users would do well to take careful steps themselves.

The Government Flexes Its Summons Muscles
ARTICLE / CLIENT ALERT
The Government Flexes Its Summons Muscles
May 26, 2023
Read time: 7 min
Two recent decisions confirmed the broad administrative summons authority of the Internal Revenue Service (IRS). In the first, the US Supreme Court resolved a circuit conflict regarding notice requirements for third-party IRS summonses. In the second, the US Court of Appeals for the Third Circuit confirmed the primacy of the Internal Revenue Code (IRC) over state law insurance and privacy laws.
Polselli v. Internal Revenue Service[1]
Mr. Polselli owed over $2 million to the IRS, was not forthcoming with payment and, moreover, appeared to be hiding assets with accommodating parties. The IRS assigned a revenue officer to track down where his assets might be. The investigation pointed to several potential repositories of relevant financial information, including a law firm, the taxpayer’s wife and a company through which Mr. Polselli had made one tax payment of $300,000. The officer issued summonses under the authority of IRC section 7602 to three banks where the law firm, the wife and the company had accounts. The officer did not give notice to any of the third parties prior to issuing the summons. After learning of the summonses from the banks, the third parties moved to quash.
The precise question was whether the third parties were entitled to notice under IRC section 7609(a)(1) and thereby had standing to move to quash the summonses or whether the exception to the notice requirement under IRC section 7609(c)(2)(D)(i), where a summons is “issued in aid of the collection of an assessment made [against the delinquent taxpayer],” applied, thus resulting in lack of standing and ultimately lack of jurisdiction. The petitioners relied upon a Ninth Circuit decision that narrowed the scope of the IRC section 7609(c)(2)(D)(i) exception to those circumstances where the delinquent taxpayer had proprietary interest in the information sought by the summons. The Sixth, Seventh and Tenth Circuits found no such limitation on the exception in part because the statute did not contain one.
The Supreme Court unanimously rejected the Ninth Circuit’s application of IRC section 77609(c)(2)(D)(i) and found the petitioners had no standing to quash. At the risk of oversimplification, the Supreme Court opened the American Heritage Dictionary of 1969, looked up the word “aid” and determined, consistent with other relevant parts of the statute, that Congress intended to use the ordinary meaning of the word “aid,” i.e., help or assist. Was the effort to locate the taxpayer’s financial connections and maneuvers through the petitioners’ bank records intended to “help” in the goal of collecting the $2 million? Yes. Implicit in this conclusion is a requirement that there is some evidence that third parties have a financial connection with the taxpayer, as opposed to the IRS randomly picking bank accounts. However, the Court declined to opine on any such requirement as that question was not specifically argued. It did note the Government’s admission that some financial connection must exist to establish “aid” in the collection of the assessment.
United States v. State of Delaware Dept. of Insurance [2]
This case centers on the intersection between the broad statutory authority granted to the IRS to collect tax and the scope of “reverse preemption” in the context of state regulation of insurance companies. In general, the IRS’s audit and collection authority preempts state laws that might otherwise prevent IRS investigations. However, the McCarran-Ferguson Act, 15 U.S.C. §§ 1011 et seq. (the MFA), broadly prohibits Congressional regulation of “the business of insurance,” leaving the states free to so regulate. What happens when the IRS collection machine is opposed by a state citing the MFA?
In this case, the IRS issued a summons directly to the Delaware Department of Insurance (the Department) in connection with the IRS’s audit of a firm and its wholly owned LLC which the IRS believed promoted micro-captive structures.[3] The IRS had previously obtained emails relating to (1) the issuance of certificates of authority by the Department to one of the firm’s insurance clients and (2) one of the Department’s directors accepting a breakfast invitation from the firm. The IRS had also determined that the Department had issued certificates of authority to 191 insurance companies which the firm helped create. As a result, the IRS wanted to know more about the communications between the Department and the firm and so issued the summons for testimony and records, including all emails between the Department and the firm. The Department agreed to respond to the summons only on the condition, pursuant to Title 18, section 6920 of the Delaware Code, that the IRS agree to keep all information confidential. The IRS declined and sued to enforce the summons in district court.
The district court reasoned that for the Department to effectively invoke the MFA, and thus prevent enforcement of the federal summons, it had to show that its effort to oppose the summons constituted the “business of insurance.” The court held that resisting an IRS summons was not an insurance business activity. The Department appealed.
After an extended discussion of relevant MFA precedent, the Third Circuit determined that the key threshold issue was whether the relevant conduct of the Department constituted the business of insurance. Declining to look behind the purpose of section 6920, the Third Circuit agreed with the lower court that the relevant conduct was the Department’s refusal to comply with the summons. Thus, the question became whether this conduct constituted the business of insurance. The state argued yes. It asserted that adherence to the confidentiality provision encourages insurers to be forthcoming in their submissions to the state regulators. Without confidentiality, insurers would hold back important information and the regulators would be hampered in determining the solvency and safety of insurers. This in turn would impact the Department’s prime mandate to protect the insured. Thus, at least indirectly, the confidentiality provision in section 6920 related to the business of insurance and the Department’s adherence to the provision by refusing to comply with the summons constituted engaging in the business of insurance. The Third Circuit disagreed, noting that if insurers make deficient filings the Department can require supplemental filings and penalize those insurers who don’t comply. In other words, whether or not the information submitted by insurers is kept confidential the Department has full authority to obtain it from the insurers, thus rendering the connection between section 6920 and the business of insurance too tenuous to support the Department’s reverse preemption claim.
Practice Point: As these cases exemplify, the IRS is generally successful in defending its summons power. It must comply with what are called the Powell factors, after the Supreme Court decision of the same name:[4] 1) legitimate audit or collection purpose; (2) the information summoned is relevant to that purpose; (3) the information sought through the summons is not already in the IRS’s possession; and (4) compliance with procedural steps required by the IRC. Once these factors are established (usually by declaration of the issuing IRS agent or officer), the summoned party has the burden to quash or modify the summons. One viable defense is to assert an applicable privilege or other defense, such as attorney-client privilege or IRC section 7525, but these typically do not apply to financial records such as bank statements, account documentation, etc. Third parties are equally subject to the summons power of the IRS as taxpayers themselves.

Top Takeaways | Successfully Deploying Digital Health in Value-Based Care
ARTICLE
Top Takeaways | Successfully Deploying Digital Health in Value-Based Care
May 26, 2023
Read time: 5 min
In this session, McDermott Will & Emery Partner Lisa Mazur moderated a panel that explored how digital health tools can support financial and clinical success under value-based care arrangements. Panelists also looked at how digital health companies can successfully demonstrate value within the value-based care framework and make themselves attractive partners to value-based care companies. The panel showcased perspectives from executives at digital health companies and companies participating in value-based care models that have successfully leveraged digital health tools.
Session panelists included:
- Jessica Beegle, Chief Innovation Officer, LifePoint
- Jamie Colbert, MD, MBA, Senior Vice President of Care Delivery, Memora Healt
- Ashul Govil, MD, MBA, Co-Founder and Chief Medical Officer, Story Health
- Maulik Majmudar, MD, Chief Medical Officer and Co-Founder, Biofourmis
- Kelsey P. Mellard, Founder and Chief Executive Officer, Sitka
Top takeaways included:
- Behind-the-scenes role. What do many successful digital health companies in the value-based care space have in common? They are operating behind the scenes, facilitating patient’s care with a trusted healthcare provider. The patient does not know they are interacting with a separate brand—rather, the companies position themselves as an extension of the local care team. This allows digital health companies to leverage the trust patients have with their physicians, increasing patient engagement as a result.
- Achieving provider buy-in. The panelists discussed several ways to achieve provider buy-in for digital health tools. A key theme was the ability of a digital health tool to integrate with providers’ existing systems and workflows. Clinicians do not want another portal to log into or another widget they are required to use. Rather, successful tools are those that are able to integrate into providers’ existing workflows and that improve those workflows as a result. Such integration requires a deep understanding of a provider’s operations and patient populations; the ability to leverage clinicians’ expertise; and engaging clinicians early during the design process and launch. The most successful digital health companies are those that are seen as a partner to providers, rather than simply being another vendor. Panelists also discussed how digital health companies need to be able to demonstrate value. While there are numerous ideas for digital health tools, successful tools will be those that deliver demonstrable outcomes.
- Successfully bridging the current fee-for-service world with value-based care. Successful digital health tools are those that can demonstrate value in both the fee-for-service (FFS) and value-based care models. Digital health companies must understand that for providers, the reality of the current system is organized around FFS. Successful companies are those that can meet providers where their systems are today, and work together towards value-based care. Panelists reflected that this requires a long view, flexible contracting models, and establishing progressive outcomes that can continue to be built upon.
- Value-based care: why now. The large penetration of Medicare Advantage (MA) is quickly changing the landscape. It provides digital health companies a large target audience that companies can meet, innovate around and innovate for, allowing companies to test their theses and adjust their models. Other accelerants include the COVID-19 pandemic and resulting economic losses on the provider side, which have caused providers to evaluate how effectively and efficiently they are providing care even under an FFS system. At the same time, patients have now experienced telehealth and care at home, and are expecting providers to continue delivering care through these new models. Finally, the proliferation of new technologies in combination with new payment models is also enabling the use of new care models. All these factors are leading providers to examine how they can provide the best-quality care at the lowest cost, and thoughtfully evaluate and reevaluate technology that will help achieve these goals, rather than piling on additional solutions.
- Looking ahead. Over the past decade, many companies focused on cutting costs and creating efficiencies. Looking forward, the panelists expect to see a new wave of companies that are focused on outcomes and creating value out of outcomes. Evidence-based tools and novel care designs can enable better quality of care that, in turn, can generate value under a value-based care model. However, the challenge is to produce evidence, especially when value is not just about the balance sheet. Providers should be asking for the evidence, but also working with digital health companies to build the evidence together.

Top Takeaways | Employer Market Perspective
ARTICLE
Top Takeaways | Employer Market Perspective
May 26, 2023
Read time: 3 min
In this session, McDermott Will & Emery Partner Patrick Healy moderated a panel that examined the expansion of value-based care in the employer market. We summarize the panel’s insights on how stakeholders can successfully implement value-based models in the employer market.
Session panelists included:
- Mark Miller, Chief Commercial Officer, Wildflower Health
- Simeon Niles, Vice President of Health Care Innovation, Morgan Health
- Carl Landry III, Director, Healthcare Strategy, Guidehouse
Top takeaways included:
- Motivated by the unsustainable increase in healthcare spending and new consolidation and joint ventures among providers and health insurers, there is an accelerated need for solutions in the employer market. If the employer market does not self-regulate, the market fears that regulators will step in.
- Regarding the relationship between employers with self-funded plans and third-party administrators (especially those owned by health insurers), there is confidence that third-party administrators’ historical relationships with employers will generate more turnkey programs producing easier-to-integrate value-based care models.
- There is a particular emphasis on how smaller employers will utilize employee data and implement value-based care models in comparison to jumbo employers.
- Significant interest in the jumbo-employer market is met with limited adoption and penetration of value-based care models when compared to the Medicare/Medicaid space. It is unclear whether these challenges are due to structural issues in the employer market limiting the pace of adoption. Such structural issues include employers as individual purchasers of coverage (as opposed to aggregate bulk purchasers); associated pools of covered lives too small for providers to take risk; lower per-enrollee healthcare spend; and lack of clarity on the optimal, most-scalable value-based model (e.g., total cost of care, quality bonuses, upside only, episode payments).

Top Takeaways | Risk-Adjustment Roulette: Strategies for Navigating the Shifting Landscape
ARTICLE
Top Takeaways | Risk-Adjustment Roulette: Strategies for Navigating the Shifting Landscape
May 26, 2023
Read time: 4 min
McDermott Will & Emery Partner Ankur Goel moderated a panel during the Value-Based Care Symposium that focused on the risk-adjustment landscape and provided insights into how the regulatory environment and contractual partnerships may continue to shift in the coming years. The panelists shared their experiences navigating the current enforcement environment and the corresponding impact on value-based care and investment opportunities.
Session panelists included:
- Jeffrey De Los Reyes, Managing Director, Alvarez & Marsal, Healthcare Industry Group
- Wayne T. Gibson, Senior Managing Director, FTI Consulting
- Kanika Sabor, Managing Director, Healthcare Disputes and Economics, Ankura Consulting
- Timothy J. Wilder, FSA, MAAA, Principal and Consulting Actuary, Milliman
Top takeaways included:
- Increased complexity of RADV audits. The methodologies for risk adjustment data validation (RADV) audits are more complex and have a broader reach than before, impacting how sampling is approached and how extrapolation is allocated back to providers by Medicare Advantage (MA) plans. The recent changes apply to US Centers for Medicare & Medicaid Services (CMS) and Department of Health and Human Services (HHS) Office of Inspector General (OIG) RADV audits, which means the potential financial risk is higher. Providers and Medicare Advantage organizations must analyze the potential impact of these changes and become better prepared to respond to these audits.
- Greater collaboration between payors and providers. The changes brought about by the RADV audits will likely encourage more collaboration between payors and providers, as both parties will need to be more knowledgeable about what goes into their payments. Payors may also have to perform more audits to reduce exposure, with involvement of the providers becoming the norm.
- Increased scrutiny on third-party vendors and providers. There will be greater scrutiny on third-party vendors, with many needing to change their processes based on stricter rules. The risk of enforcement actions under the False Claims Act is evolving, from targeting plans to targeting providers and third parties. Currently, the entire ecosystem has risks and everyone needs to be aware of the potential impact of these new changes.
- Impact of the new risk-adjustment model. The new model will force adjustments in how entities operate in the risk-adjustment space. It is expected to shift the focus from coding to more concentrated samples and adherence to compliance, ensuring that things are done mindfully. This may lead to less emphasis on chart reviews and a greater focus on prospective strategies, provider education, and collaboration between payors and providers.
- Continued growth and challenges in value-based care (VBC). Despite changes in the risk-adjustment landscape, VBC remains a viable investment and a fundamental approach for aligning payers and providers. However, the adjustments may prolong the investment period and require more coordination and strategic planning. As MA grows in popularity, organizations must adapt to the new rules and ensure that their strategies align with the evolving risk-adjustment environment.

Investing In a Healthier Future: The Investor’s Perspective On Value-Based Care
ARTICLE
Investing In a Healthier Future: The Investor’s Perspective On Value-Based Care
May 26, 2023
Read time: 4 min
In this session, McDermott Will & Emery Partner Joel Rush moderated a discussion exploring investors’ interests in, opinions on and strategies for entering the value-based care (VBC) market. The panel discussed factors taken into consideration when choosing if and when to invest in VBC opportunities, issues that arise when collaborating with health systems, and ways to evaluate risk models and support improved care delivery.
Session panelists included:
- Lauren Brueggen, Partner, Heritage Group
- Devin Carty, Chief Executive Officer, Martin Ventures
- Roger Kueny, Senior Vice President of Corporate Development, Alignment
- David Pontius, Partner, WindRose Health Investors
- Karey Witty, Managing Director, Valtruis
Top takeaways included:
- When it comes to investing in VBC, the tailwinds are just beginning to pick up after the COVID-19 pandemic reduced reimbursement volume. During that time, physician practices that were leaning on fee-for-service (FFS) reimbursements saw their volumes drop close to zero during the COVID-19 pandemic. Hospitals began to get crushed by the rates, and much of the volume has yet to return to normal. One way to solve this problem is by moving physician practices into VBC and to demonstrating that VBC is a bonus, not a penalty, and probably the only way to get back to the earnings they previously had. Also, when looking at hospital systems, investor-based hospitals performed significantly better during the pandemic. Innovative programs like the Accountable Care Organizations Realizing Equity, Access, and Community Health (ACO REACH) model are showing hospitals and physicians that the market is experiencing a technology shift, and VBC provides a framework in which multiple constituents can work together and achieve mutual success.
- Key factors to look for when evaluating VBC investment opportunities include having a sustainable reimbursement mechanism that provides a “win” for both sides and can generate savings. This analysis looks at much more than just risk scoring. Other factors include whether the hospital is focusing on areas where they are losing money or simply breaking even, and whether the target companies are looking at technology solutions that can take workflow changes off the shoulders of physicians so they can focus on practicing quality care. “Innovation” and “disruptiveness,” when combined with an effective risk distribution within the entity (e.g., toward Medicare Advantage of commercial populations, and across service lines), promote the creation of better ways to provide patient care.
- Challenges in partnering or collaborating with health systems in VBC include (1) changing the operation perspective from do-it-yourself to partnership, (2) selecting the right deal or deal structure (i.e., joint venture or master services agreement (MSA) model), and (3) aligning the incentives for the organization to shift to VBC.
- Opportunities in partnering or collaborating with health systems in VBC are emerging due to (1) hospitals’ willingness to shift to VBC and (2) the shifting view on owning primary care infrastructure (i.e., employing versus partnering with primary care physicians).
- Effective evaluation of VBC provider models requires (1) determining the right risk model for each specialty and (2) identifying the path to better quality of care.
- Investors have noted the following areas of emerging interest in VBC investment: (1) Medicare, as it is the largest payor and responsible for much of the push toward VBC, (2) scaling risk-based Medicaid, (3) behavioral health risk-based models and (4) a push into southern states.

Top Takeaways | 2023 PPM-ASC Symposium | Specialty Spotlight: Urology
ARTICLE
Top Takeaways | 2023 PPM-ASC Symposium | Specialty Spotlight: Urology
May 26, 2023
Read time: 3 min
In this session, the panelists discussed the latest trends and unique dealmaking considerations impacting the urology industry.
Session panelists included:
- Kevin Palamara, Managing Director, Provident Healthcare Partners
- Mitchell Hollander, MD, Chief Executive Officer, Michigan Institute of Urology
- Jitesh Patel, MD, President & Chief Executive Officer
- Joseph Parise | Partner, McDermott Will & Emery (Moderator)
Top takeaways included:
- Value-based care opportunities exist in the urology space, including around sub-capitation models and episodic reimbursement; however, access to and collaboration with payors is a critical component to ensure those opportunities are successful. Platforms and independent practices can work with payors and managed care organizations to ensure alignment on appropriate reimbursement rates to create better outcomes, quality and access—all at lower cost. To date, these models have not been broadly implemented, but operators have identified managed care as an area for potential growth.
- Competition with hospitals and employed urology models are significant challenges in the industry and with respect to developing ancillaries. Generating income repair for physicians and ensuring alignment among the stakeholders are key components to countering competition and developing successful urology platforms.
- It is expected that over the next 10 years there will be a significant shortage of urologists, as the number of retiring urologists continues to exceed the number of new urologists entering the market. Industry participants need to prepare for this impending shortage of urologists by continuing to develop unique staffing models, creating programs to attract and retain talent, and leveraging advanced practice practitioners (e.g., nurse practitioners (NPs), physician assistants (PAs)).
- Industry participants must innovate and focus on organic growth to continue to develop their businesses, including, among other methods, by implementing horizontally or vertically integrated platforms and utilizing surgery centers, in-office dispensing facilities and labs to do so.

Top Takeaways | 2023 Physician Practice Management & ASC Symposium 2023 | Fraud & Abuse Risk Mitigation and Enforcement Trends
ARTICLE
Top Takeaways | 2023 Physician Practice Management & ASC Symposium 2023 | Fraud & Abuse Risk Mitigation and Enforcement Trends
May 26, 2023
Read time: 5 min
In this session, McDermott Will & Emery Partners Denise Burke, Tony Maida and Monica Wallace discussed top issues and enforcement trends that physician practice management companies (PPMs) and ambulatory surgery centers (ASCs) should watch to mitigate their fraud and abuse risk. The panel also discussed the potential impact of recent regulatory changes on future enforcement priorities.
Session panelists included:
- Denise Burke, Partner, McDermott Will & Emery
- Tony Maida, Partner, McDermott Will & Emery
- Monica Wallace, Partner, McDermott Will & Emery
Top takeaways included:
- The federal government recently released False Claims Act recovery data for 2022. While the recovery amounts went down, the number of reported cases actually went up. We anticipate seeing more COVID-19-related enforcement actions. We are also seeing continued government focus on financial arrangements with physicians, including transactions involving physicians receiving preferential investment terms, such as below-fair-market-value purchase prices.
- In the most recent revision to the Stark rules, there is a new ability to cure compensation errors. Specifically, if a designated health services (DHS) entity has a compliant written compensation arrangement with a physician and discovers a payment error during the term of the arrangement or within 90 days of termination, the entity can correct or reconcile the compensation error and there is no need to submit a self-disclosure. The US Centers for Medicare & Medicaid Services (CMS) recently said that errors could even be fixed after 90 days from termination, but this requires a close analysis of the facts.
- The federal government has started to take steps to settle Stark Self-Referral Disclosure Protocol matters more quickly. Many clients have been waiting six to seven years to resolve disclosures. Last fall, CMS started to implement a first-in, first-out / last-in, last-out approach and we are seeing settlements of disclosures submitted as recently as six months ago. Unfortunately, we are also seeing higher settlement dollar values for more technical issues, up to as high as 10% (as opposed to the 2–3% range we have become accustomed to seeing).
- In a recent CMS frequently asked questions (FAQ), the agency stated that physicians that have been mailing prescriptions to patients’ homes do not qualify for the location requirement of the in-office ancillary services exception (meaning, according to CMS, that once the federal public health emergency ends on May 11, 2023, and the COVID-19 waiver-on-location requirement ends with it, this practice will need to cease). There is a fair amount of controversy surrounding whether this FAQ is consistent with the regulation. Practices should evaluate their drug-mailing practices and consider whether there are alternative arrangements while this issue remains in flux.
- CMS has recently issued a Stark Self-Referral Disclosure Protocol form change to streamline the process. In connection with group practice issues, CMS added a requirement to include the definition of the date of discovery of the violation. This used to be tied to the definition of identifying the overpayment according to the overpayment regulation; now, it is a more nebulous “how did you find it?” exercise.
- The Department of Health and Human Services (HHS) Office of Inspector General (OIG) has also changed its FAQ process and created a pathway for obtaining a quicker response whereby questions are submitted for an FAQ response (as compared to submitting a formal advisory opinion request). We note that it remains to be seen how this plays out—it is easier and faster to say “No” or “This poses risk,” than to say “Yes.”
- OIG recently issued an advisory opinion on patient inducement questions that has been generating discussion. In the advisory opinion, OIG approved the practice of giving patients a Visa gift card of up to $75 to encourage them to submit a sample for their at-home colorectal cancer screening test. This is notable because cash and cash equivalents have historically been unprotected. OIG weighed numerous factors in the opinion when it decided that the practice was ultimately low risk. (Reasons for determining low risk include the following: the test is prescribed by a doctor; it is a screening that is intended to be performed very three years and aimed at catching early indications of a large public health issue; and the gift card enticement is not offered until patients have been delinquent in submitting their samples after multiple follow-ups, among other rationale.) The opinion is helpful in demonstrating that the government can be more flexible in its thinking when presented with compelling facts.

Top Takeaways | 2023 PPM-ASC Symposium | Specialty Spotlight: Behavioral Health
ARTICLE
Top Takeaways | 2023 PPM-ASC Symposium | Specialty Spotlight: Behavioral Health
May 26, 2023
Read time: 3 min
In this session, panelists provided an in-depth look at focus and sub-focus areas within the behavioral health industry. Our panel also discussed supply and demand imbalances, merger and acquisition (M&A) transaction considerations, reimbursement trends, digital and telehealth services, and other issues companies within the behavioral health market should consider.
Session panelists included:
- Gaurav Bhattacharyya, Founder and Chief Executive Officer, Geode Health
- L.A. Galyon IV, Managing Partner, Brentwood Capital Advisors
- J.R. Green, Chief Executive Officer, Psychiatric Medical Care
- Rita Ratner, Managing Director, Farragut Square Group
- Jake Stark, Vice President, WindRose Health Investors
- Moderator: Marshall Jackson, Partner, McDermott Will & Emery
Top takeaways included:
- Supply and demand imbalances have been exacerbated, as there is an increase in mental disorders and care models are trying to meet the needs.
- The industry is seeing an increase in integration of mental and physical health.
- Companies have been focusing on preventive outpatient care to help reconcile staffing imbalances, as well as using a mix of psychiatrists and various mid-level providers.
- Clinical reputation and clinical alignments are two major factors investors examine when evaluating practices to acquire.
- Payors are expanding reimbursement for various behavioral health services; however, behavioral health is not ready for value-based care—a key issue being the difficult-to-measure outcomes across behavioral health services.
- Digital health is a key focus area in behavioral health; however, the effectiveness of digital health tools is predicated on the types of services being provided and the adoption of these tools by patients, consumers and providers. Many behavioral health providers use a hybrid in-person and telehealth approach to connect with their patients, as opposed to a digital-only platform.

Top Takeaways | 2023 PPM-ASC Symposium | ASC 2.0 Selected Trends: Bundled Payments, Tech & Anesthesia
ARTICLE
Top Takeaways | 2023 PPM-ASC Symposium | ASC 2.0 Selected Trends: Bundled Payments, Tech & Anesthesia
May 26, 2023
Read time: 3 min
In this session, panelists discussed recent technological, payment and regulatory trends in the ambulatory surgery center (ASC) space, with a focus on implementing and managing bundled payments. The group also explored complex questions raised on structuring and risk, leveraging technology to streamline ASC operations and maximize business outcomes, and structuring anesthesia arrangements for ASCs.
Session panelists included:
- Jason Scalise, MD, Chief Growth Officer, HOPCo
- Piper Su, Chief Growth Officer, triValence
- Tony Maida, Partner, McDermott Will & Emery
- Moderator: Ryan Higgins, Partner, McDermott Will & Emery
Top takeaways included:
Bundled Payments
- There has been growing interest in expanding the time frame or scope of services included in a bundled payment. Such a shift in focus could help align behaviors and manage the appropriateness of care. But without appropriate real-time data, there are significant challenges in determining the scope and pricing of a bundle.
- As the scope of clinical services provided safely in an ASC has continued to expand, there has been a shift from inpatient to outpatient procedures, and driving them to ASCs. The ASC community can play an integral role in determining scope and pricing of bundles.
- Bundled payments have had a somewhat spotty reputation in terms of success. One challenge is that the payor may adjust the target annually, leading to cost-cutting and a race to the bottom until there is no opportunity for additional savings. Going forward, bundled payment programs should be developed with an eye toward sustainability, building in inflationary trends, demographic shifts and trends around acuteness of care.
Technology in the ASC Space
- As ASC procedure volume increases, more tech companies are focusing on the ASC sector, but ASCs are still just starting to get access to some of the technologies that other sectors have had for a decade or more.
- When evaluating new products, ASCs should ask for references from other users and make sure claims about the technology are backed up by data and user experience.
Anesthesia Arrangements
- There are a few different models for providing anesthesia in ASCs. Given the shortage of anesthesia service providers, ASCs may need to be flexible in selecting a model and pay careful attention to Anti-Kickback Statute compliance and corporate practice of medicine considerations.
